Effect of Mitomycin C on the Size of Antrostomy after Endoscopic Sinus Surgery

Kim, Seon-Tae; Gang, Il-Gyu; Cha, Heung-Eog; Ha, Jong-Su; Chung, Yoo‐Sam

doi:10.1177/000348940611500904

Cited by 18 publications

(22 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It was finally reported that single dose inraoperative MMC did not produce any difference compared to control side in frontal recess narrowing [20]. Finally, in the study of Kim et al [11], measuring the narrowing of maxillary sinus ostium enlarged after ESS at first, third and sixth months, it was reported that topical MMC decreased ostium narrowing in a statistically significant manner only in first month and that no difference was established at third and sixth months.…”

Section: Discussionmentioning

confidence: 95%

“…In the study of Park et al [18], 0.4 and 1 mg/ml concentrations were compared, with no significant difference between them. In clinical studies, concentrations of 0.4 and 0.5 mg/ml were used [11,19,20]. In the present study, MMC was applied at the concentration of 0.6 mg/ml.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, 80-90% success rate was obtained in the treatment of keloids with topical MMC use [9]. In ENT, it was used in the treatment of chronic sinusitis, endoscopic dacryocystorhinostomy, laryngeal and tracheal stenosis, and coanal atresia [10][11][12][13].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The effects of repetitious topical use of mitomycin C on antrostomy patency in maxillary antrostomy created rabbit model

Kavuzlu

Arslan

Taştan

et al. 2011

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

The aim of our study was to investigate the effect of the topical use of mitomycin C (MMC) intraoperatively in single dose and intra-postoperatively in two doses on the narrowing of antrostomy in maxillary rabbit sinus antrostomies created experimentally. And also to determine the local and systemic side effects of topical MMC. With this objective, 0.6 mg/ml MMC was used to the first group at single dose and to the second group intraoperatively and on third day postoperatively in two doses topically for 5 min. After 8 weeks, although the mean area of antrostomy was larger than that in the control side in the first group, which received single dose MMC, the difference was not statistically significant (p = 0.287). The second group received two doses, and the antrostomy areas were found to be significantly larger than the controls (p = 0.05). Overall, the sides that received MMC were significantly larger (p = 0.029). From the point of histopathological examination of the tissue, it was seen that two-dose MMC increased the edema indicating inflammation and antrostomy resolved with normal respiratory tract epithelium. It was shown by measuring the blood values that nephrotoxic and myelosupressant effect of MMC occurring in systemic use did not occur with single or double dose topical use. Our results demonstrate that even if the number of cases was low, two doses of topical MMC usage prevent the narrowing of antrostomy while single dose MMC does not. And two-dose topical MMC usage does not have local and systemic side effects.

show abstract

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The effects of repetitious topical use of mitomycin C on antrostomy patency in maxillary antrostomy created rabbit model

Kavuzlu

Arslan

Taştan

et al. 2011

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

show abstract

“…19 Also, mucociliary clearance of nasal mucosa was found to be unaffected by application of MMC. 20 Subconjunctival MMC injection (0.2 mg/ml) has been used in the treatment of ocular cicatricial pemphigoid without any complications. 21 Recently, submucosal injection of MMC has been used for esophageal strictures without any complications and recurrence.…”

Section: Discussionmentioning

confidence: 99%

“…Numerous clinical and basic science studies have pointed to the possible beneficial effects from long-lasting application of MMC. [15][16][17][18][19][20][21] With the aim of achieving higher drug concentration and long-lasting biologic effect, the authors devised a technique of intramucosal injection of MMC in a circumostial fashion at 4 points during DCR. The purpose of present study was to evaluate the safety and efficacy of this new technique in DCR and to evaluate its outcomes.…”

mentioning

confidence: 99%

Circumostial Injection of Mitomycin C (COS-MMC) in External and Endoscopic Dacryocystorhinostomy

Kamal

Ali

Naik

2014

Ophthalmic Plastic &Amp; Reconstructive Surgery

View full text Add to dashboard Cite

show abstract

Topical use of MMC in the upper aerodigestive tract: a review on the side effects

Veen

Dikkers

2009

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

Not much is known about the side effects of mitomycin C (MMC), an anti-fibrogenetic agent, in the upper aerodigestive tract. However, its use in ophthalmology is widely known and without quantitatively important side effects. A literature review was performed for side effects of MMC in the upper aerodigestive tract. Forty-six articles, describing the use of MMC to prevent scarring, were retracted from PubMed. Thirty-two are human studies. MMC is used in different concentrations (0.1–10 mg/ml) with different application times (2–5 min) and frequencies (up to 4 times). Five hundred and thirty-eight patients were included in those publications, of whom 19 developed side effects (3.53%). No side effects developed in studies, where post-application irrigation with saline was reported. The longest mean follow-up period is 75.5 months. Direct relations between the reported side effects and MMC seem absent in most studies. Serious complications seem to occur when MMC is used in high concentrations. Unfortunately, sometimes crucial information is lacking. One patient was described who supposedly developed laryngeal carcinoma after repeated treatment of hyperkeratosis and anterior commissure webbing. Animal studies show that excessive fibrin production can lead to acute airway obstruction. In conclusion, topical application of MMC on a wound with consecutive irrigation with saline can be performed safely to prevent scar formation in circular structures of the upper aerodigestive tract. Long-term yearly control of the application site seems advisable.

show abstract

Effect of Mitomycin C on the Size of Antrostomy after Endoscopic Sinus Surgery

Abstract: Topical MMC application may have a short-term effect in maintaining the patency of the antrostomy site. However, it does not seem to improve the relative size over an extended period of time.

Cited by 18 publications

References 29 publications

The effects of repetitious topical use of mitomycin C on antrostomy patency in maxillary antrostomy created rabbit model

The effects of repetitious topical use of mitomycin C on antrostomy patency in maxillary antrostomy created rabbit model

Circumostial Injection of Mitomycin C (COS-MMC) in External and Endoscopic Dacryocystorhinostomy

Topical use of MMC in the upper aerodigestive tract: a review on the side effects

Contact Info

Product

Resources

About